A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb
Authors:
Abstract
Background. Forty-two patients with measurable recurrent melanoma of the lower limb were treated according to a double-perfusion schedule. Methods. To assess the advantage of this schedule compared with that of a single-perfusion treatment, a retrospective study was done comparing the 42 patients with 45 patients who had undergone a single-perfusion procedure. Both groups were well balanced with respect to patient and tumor characteristics. For patients treated with a double schedule, the dose of melphalan given in the first perfusion was low (6 mg/l; 1 hour; normothermic conditions) to make it possible to perform a second perfusion (9 mg/l; 1 hour; normothermic conditions) with a planned short interval of 3–4 weeks. In the singleperfusion group, a normothermic perfusion with 10 mg melphalan/l was performed. Results. The toxicity did not differ between the two treatment modalities. The response rate was significantly higher in the double-perfusion group (90% versus 68%; P = 0.007) because of a higher complete remission rate (76% versus 48%; P = 0.006). In both groups, approximately half of the patients with complete remission experienced disease recurrence in the perfused area (50% versus 52%). No significant differences were seen in the two groups in the regional node recurrence rate (33% in the double-perfusion group versus 20% in the single-perfusion group), distant recurrence rate (50% in the double-perfusion group versus 58% in the single-perfusion group), and their corresponding recurrence-free intervals. The overall 3-year survival rate was 46% in both groups. Conclusion. In the patient groups studied, the double-perfusion schedule shows a better complete remission benefit than does the single-perfusion procedure. No differences are seen in limb, regional node, and distant recurrence rates in the two groups. Thus, additional improvement of the perfusion methodology is warranted.Keywords
This publication has 11 references indexed in Scilit:
- Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limbEuropean Journal of Cancer, 1993
- Natural history and selective management of in transit melanomaJournal of Surgical Oncology, 1990
- Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limbBritish Journal of Surgery, 1990
- Preliminary Results of a Double Perfusion Schedule with Melphalan in Measurable Melanoma1990
- Patterns of Relapse in 1001 Consecutive Patients With Melanoma Nodal MetastasesArchives of Surgery, 1989
- Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusionCancer, 1989
- Multivariate analysis of prognostic factors in regional cutaneous metastases of extremity melanomaCancer, 1988
- Objective Regression of Unexcised Melanoma in-Transit Metastases After Hyperthermic Isolation Perfusion of the Limbs with Melphalan1983
- Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactionsEuropean Journal of Cancer and Clinical Oncology, 1982
- Chemotherapy of CancerAnnals of Surgery, 1958